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Chlamydia trachomatis (CT) is a pestilent infection affecting upwards of 90 
million people worldwide.  An efficacious vaccine is needed to control the morbidities 
and rising healthcare cost associated with genital CT infection.  We have established that 
protection against chlamydia infection parallels with a high frequency of T helper Type 1 
cells and the associated antibodies.  The current study focuses on the induction of innate 
immune responses involved during Chlamydia infection by a Vibrio cholera ghost-based 
(VCG) vaccine vector.  THP-1 cells were used for dose and kinetic experiments.  HeLa 
cells were used for infectivity assays.  Based on preliminary studies, we hypothesized 
that the induction of immune responses by a VCG-based vaccine involves multiple innate 
immune signaling. Multiplex assay was used to measure T helper Type I and Type II 
cytokine secretion by THP-1 monocytes (Mn) or macrophages (Mϕ).  
Immunostimulatory cytokine secretion was significant when both cell morphologies were 
pulsed with VCG or VCG/murine splenocytes. We concluded that this secretion was 




pulsed with Chlamydia elementary bodies alone, enhancing the innate immune response 
during infection.  Cellular supernatants (conditioned media) containing Th1-type and 
Th2-type cytokines were used to culture Chlamydia-infected HeLa cell monolayers.  
Infected HeLa monolayers cultured in the conditioned media were significantly less 
infected (968 IFUs) versus HeLa monolayers cultured in Earle’s minimum essential 
media (16,486 IFUs; p<0.001).  We concluded that factors contained in conditioned 
media prevent and/or significantly reduce infection by Chlamydia and the development 
of inclusion forming units.  
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 Chlamydia trachomatis (CT) is an obligatory intracellular prokaryotic pathogen 
(1) that causes genital Chlamydia infection.  CT causes the most common bacterial 
sexually transmitted infections (STI) in the United States and one of the ten most 
common STIs worldwide.  Each year an estimated 90 million sexually transmitted 
Chlamydia trachomatis infections occur around the world with more than two-thirds of 
these cases occurring in developing countries (2).  The sequelae arising from CT 
infection include pelvic inflammatory disease (PID), ectopic pregnancy, and infertility, 
and have substantial psychological, public health, and economic implications (2).  
Understanding the molecular mechanisms involved in the induction of chlamydia 
infection immune responses will help in developing effective long-term treatment (2-10). 
Chlamydia infection enhances the risk of Human Immunodeficiency Virus (HIV) 
-1 acquisition and transmission (11), and as such, this combination increases the public 
health problem worldwide (8).  Treatment of symptomatic infections does not prevent 
reinfection nor affect established pathology (8, 12-13).  The potential severity of 
complications resulting from infections with C. trachomatis, particularly in women, 
coupled with enhanced HIV-1 transmission and inability to prevent reinfection with 
antibiotic treatment provide strong motivation to prevent Chlamydia infection through 




An efficacious chlamydial vaccine should induce broad-based, long-lasting immunity (3, 
8).  A better understanding of the correlates of long-lasting, cross protective immunity 
will support the development of better protective vaccine strategies. This understanding 
will play a major role in reducing the economic burden on the public healthcare system 
and the high treatment costs of infectious complications (2-3, 7-8).  Previous studies 
conducted by Eko et al. (2004) suggest that achievement of long-term, cross-protective 
chlamydial immunity is possible and would require the appropriate delivery of specific 
multiple chlamydial antigens and effective immunomodulation (12).  Studies of the 
molecular mechanisms involved in Chlamydia infection have examined T-cell control 
and the role of nitric oxide (15), and the role of dendritic cells and Toll-like receptor 
(TLR) 9 in innate immunity (16).  TLRs are a family of type I transmembrane receptor 
proteins that are required for the recognition of various pathogen-associated molecular 
patterns (PAMPs) expressed by a diverse group of infectious microorganisms, resulting 
in the activation of host immune responses.  In the present study, the involvement of 
TLR2 and TLR4 during Chlamydia infection was evaluated.  The molecular involvement 
of TLR2 and TLR4 in Chlamydia infection has been studied more extensively than the 
other nine [human] TLRs, and the Chlamydia trachomatis ligand for TLR4 is well 
defined.  However, the Chlamydia trachomatis ligand for TLR2 is not, as it recognizes a 
wide array of PAMPS in heterodimer complexes with TLR1 or TLR6. TLR2 and TLR4 
are largely located on the cell surface.  This study investigated TLR signaling in, and 




investigated the intrinsic structural properties of our Vibrio cholera ghost (VCG) vector 
and the presence of TLR ligands on the bacterial ghost envelope. 
 Recent studies in animal models of genital chlamydial disease revealed that early 
recruitment of dendritic cells and specific T helper type-1 (Th1) cells into the genital 
mucosae is crucial for reducing the severity of the acute phase of a cervico-vaginal 
infection and arresting ascending disease (6, 17). The CD4+ Th1 and CD8+ T cells and 
their cytokines, especially gamma interferon (IFN-γ), are crucial for anti-chlamydial 
immunity in mice (17). These immune effectors are therefore important for preventing 
major complications of genital chlamydial infection (6, 17).  The recruitment of Th1 cells 
into genital mucosae after chlamydial infection has previously been demonstrated (17). 
This recruitment would require obligatory interactions among chemokines, chemokine 
receptors, and cell surface molecules such as the major histocompatibility complex 
(MHC), addressins, co-receptors, co-stimulatory and adhesion molecules (17). Factors 
that regulate the induction, recruitment, and persistence of immune effectors (especially 
Th1 cells) in the genital mucosal site control long-term genital mucosal immunity and are 
particularly important for anti-chlamydial immunity (17). 
 In this respect, studies in animal models and corroborating clinical findings in 
humans have revealed that an infected host develops immunity against C. trachomatis 
(18), which correlates with a strong T helper type-1 cell response and a complementary 
antibody response (18). Thus, a vaccine that elicits this profile of specific immune 




The majority of successful vaccines have been derived from either inactivated organisms 
or live-attenuated organisms (19). One goal of vaccine research is to develop a single-
dose, orally or nasally administered, recombinant vaccine that induces long-lasting 
mucosal and systemic immunity (2-3, 8).  As recombinant proteins are poorly 
immunogenic (3), particularly when given by mucosal routes, their use in vaccines 
requires co-administration of an adjuvant (20).  The recombinant Vibrio cholera ghost 
(rVCG) platform has been shown to be an effective carrier and delivery system for cloned 
CT proteins, eliciting chlamydial-specific immune responses following immunization (8, 
12-13).  In the present study, we evaluated the immunogenicity of our VCG vector by 
elucidating the immune response and signaling pathways elicited by the vector in the 
host.  Furthermore, we observed how it may enhance the innate immune response during 
Chlamydia infection. 
The purpose of this study is to examine immune activation of pathogen-associated 
molecular pattern recognition receptors (PRR) and elucidate the molecular mechanisms 
involved in the induction of immune responses during Chlamydia infection by a VCG-
based vaccine vector.  Studies were carried out to support our hypothesis that the 
induction of immune responses by a VCG-based vaccine involves multiple innate 








2.1 Chlamydia trachomatis biology 
Chlamydia trachomatis are coccoide, gram-negative microbial pathogens which 
are metabolically deficient in their ability to synthesize ATP and thus have an obligate 
intracellular life cycle.  The pathogen is of the order Chlamydiales and currently has one 
family, the Chlamydiaceae, containing two genera, Chlamydia and Chlamydophila (21).  
Three species of Chlamydia exists: C. trachomatis, strictly a human pathogen, C. psittaci, 
a pathogen of lower mammals (22) e.g., birds, and C. muridarum, a mouse/hamster 
pathogen. 
Chlamydia trachomatis consists of 15 serovars that cause many human diseases, 
including ocular trachoma (serotypes A to C); urethritis, epididymitis, cervicitis, and 
salpingitis (serotypes D to K); and lymphogranuloma venereum (LGV; serotypes L1 to 
L3) (23). Serotypes A to K (trachoma biovar) primarily infect columnar epithelial cells of 
the mucous membranes, while serotypes L1 to L3 (LGV biovar) also proliferate in 
lymphatic tissue and cause a more systemic infection. The third biovar of C. muridarum 
is the murine biovar, consisting of two strains, MoPn, which causes mouse pneumonitis 
but does not infect humans, and SFPD, concurrent with a causative agent of proliferative 
ileitis, obtained from a hamster (127). In addition, three serogroups among the human 





(serotypes B, Ba, D, Da, E, L1, L2, and L2a), the C complex (serotypes A, C, H, I, Ia, J, 
K, and L3), and the intermediate group (serotypes F and G) (23). 
Serotype specificity is conferred by the major outer membrane protein (MOMP; 
the product of the omp1 gene). MOMP constitutes ∼60% of the protein mass of the 
chlamydial outer membrane and has been shown to have porin-like characteristics in vitro 
(23). 
2.2 Chlamydia trachomatis infection and modulation of host cell functions 
Chlamydia trachomatis has a significant impact on host signaling pathways 
causing substantial changes to cellular transcription as well as cell damage (24).  What 
distinguishes Chlamydia from other bacteria is their intracellular parasitism, responsible 
for the chronic and asymptomatic course of infection (25).  Elucidating the molecular 
mechanisms Chlamydia infection engages to perpetuate the use of its effector proteins to 
“trick” host cell defenses will help in developing a system for long-term immunity that 
could reduce and/or eliminate reinfection. 
Chlamydiae undergo a distinct developmental cycle, converting between two 
morphologically and functionally discrete forms - the elementary body (EB) and the 
reticulate body (RB). The basic cycle follows this sequence: (I) attachment and 
internalization; (II) EB to RB differentiation; (III) remodeling of the parasitophorous 
vacuole (“inclusion”) and bacterial replication; (IV) inclusion expansion and transition of 
RB into EB; and (V) release of bacteria from the host cell and infection of new target 
cells by EBs (fig. 1) (6).  Studies based on expression analysis (Belland et al., 2003; 





Subtil et al., 2005), function-based screens (Sisko et al., 2006) and bioinformatics 
(Samudrala et al., 2009) have yielded many candidate Chlamydia proteins that may 
participate in the manipulation of host cellular processes (13). 
 
Figure 1. Schematic illustration of the infectious cycle of Chlamydia trachomatis.  The Chlamydia 
trachomatis infectious cycle and modulation of host cell functions. Chlamydia infection begins when an 
elementary body (EB) binds to the host cell surface (I). At this stage effector proteins injected into the host 
via the type III secretion system (T3SS) facilitate bacterial entry. Following endocytosis, EBs transition to 
reticulate bodies (RBs) (II). New effectors are secreted and the bacterial vacuole is modified by bacterial 
inclusion membrane proteins (Incs) to limit fusion with the host degradative compartments while 
promoting contact with other host organelles and factors, including Rab proteins. The inclusion interacts 
with the Golgi apparatus, multivesicular bodies (MVBs) and lipid droplets (LDs). LDs can be directly 
translocated into the inclusion lumen for nutrient delivery (III). During infection, host cell death and 
immune defenses are inhibited. Approximately midway through the infectious cycle, bacterial replication 
becomes asynchronous and RBs re-differentiate into EBs (IV). Late in the cycle, the inclusion is packed 
with EBs and fills almost the entire cell volume. Eventually, the inclusion and host cell rupture releasing 





The word chlamys is Greek for “cloak draped around the shoulder.”  This 
describes how the intracytoplasmic inclusions caused by the bacterium are “draped” 
around the infected cell’s nucleus (26).  Once established in this niche, the inclusion can 
selectively interact with organelles that provide factors essential for chlamydial 
development such as eukaryotic lipids, including sphingolipids (Hackstadt et al., 1996; 
Moore et al., 2008), cholesterol (Carabeo et al., 2003) and glycerophospholipids (Wylie 
et al., 1997). While sphingolipids and cholesterol isolated from bacteria are not modified, 
fatty acids in the Sn2-position of host glycerophospholipids are exchanged with 
Chlamydia-derived branched chain fatty acids (Wylie et al., 1997; Su et al., 2004). Lipid 
transport to the inclusion occurs through largely undefined pathways (13). 
The Chlamydia trachomatis infectious cycle and modulation of host cell functions 
begins when an elementary body binds to the host cell surface.  At this stage effector 
proteins injected into the host via the type III secretion system (T3SS) facilitate bacterial 
entry.  Following endocytosis, EB reorganize into reticulate bodies.  New effectors are 
then secreted and the bacterial vacuole is modified by bacterial inclusion membrane 
proteins (Incs) to limit fusion with the host degradative compartments while promoting 
contact with other host organelles including the nucleus.  The inclusion interacts with the 
Golgi apparatus, multivesicular bodies (MVBs), and lipid droplets (LDs).  LDs can be 
directly translocated into the inclusion lumen for nutrient delivery.  During infection, host 
cell death and immune defenses are inhibited.  Approximately midway through the 
infectious cycle, bacterial replication becomes asynchronous and RB re-differentiate into 





volume.  Eventually, the inclusion and host cell rupture releasing infectious EB into the 
extracellular space for reinfection (13). 
2.3 Innate and Adaptive Immunity to Chlamydia 
In the genital tract, Chlamydia trachomatis infects primarily epithelial cells and 
requires Th1 immunity for optimal clearance.  Innate immunity plays a role in controlling 
chlamydial infections (27).  Natural killer (NK) cells and neutrophils are the first cells 
that are recruited to the site of a chlamydial infection.  These cells are important in innate 
immunity and have been implicated in the initial control of chlamydial infections.  In 
fact, neutrophils are usually the first host cells recruited to an infectious site (28-29), and 
their likely role is to reduce the initial chlamydial infection and limit it from spreading 
(30). NK cells are known to be involved primarily in viral infections and cancer but have 
also been shown to be important in the early elimination of intracellular bacteria (31-32). 
Cytokine production by epithelial cells and dendritic cells (DC) has been implicated in 
NK cell INF-γ production during a chlamydial challenge.  Cytokines (interleukin (IL)-12 
and IL-18, respectively) produced by DC and human epithelial cells induce NK cells to 
secrete IFN-γ (33).  IFN-γ is important for inhibiting the growth of chlamydia (34).  Just 
as important, IFN-γ is one of the main cytokines for the induction of a Th1 immune 
response.  Furthermore, early IFN-γ production by NK cells modulates DC to down-
regulate the Th2 response, thereby allowing expression of strong Th1-mediated 
immunity, which has been shown to be essential for the resolution of Chlamydia infection 
(35). IFN-γ down-regulation of the transferrin receptor (36), which is needed for the 





iron to the bacterium.  Most Chlamydia species require tryptophan for survival (37).  
IFN-γ induces the expression of the cellular tryptophan-decyclizing the enzyme 
indoleamine-2,3-dioxygenase (IDO), which degrades tryptophan. 
Chlamydia-specific antibodies play a role in C. trachomatis protective immunity 
(38-39), and numerous C. trachomatis proteins have been shown to induce antigen-
specific antibodies (40).  B cells may not be important for initial chlamydial infection but, 
instead, play an important role in the secondary memory response (41-42).  There are 
several possible mechanisms by which B cells modulate immunity during reinfection 
which include, but are not limited to antibody-mediated neutralization and opsonization 
(43), antibody-dependent cellular cytotoxicity (ADCC), the formation of antigen-
antibody complexes that bind Fc receptors on APC enhancing phagocytosis and antigen 
presentation to CD4
+
 T cells (44). 
Natural killer T cells (NK T cells) have a role in protective Th1 immunity against 
Chlamydia (45).  These granular cytolytic lymphocytes are able to destroy infected and 
cancerous cells without prior sensitization and also secrete cytokines that are important in 
both innate and adaptive immunity.  Furthermore, these cells have been implicated in 
regulating innate (macrophages), natural killer, and dendritic cells) and adaptive (B and 
conventional T cells) immune cells (46-48). 
Mϕ migrate to chlamydial infection sites (49), phagocytose bacteria (50), and 
produce pro-inflammatory cytokines (51-52).  C. trachomatis destruction inside Mϕ has 
been associated with host cell autophagy, a process by which cells degrade cytoplasmic 





cells (56).  Furthermore, IFN-γ has been shown to enhance both autophagy and up-
regulation of MHC class II molecules in Mϕ (54, 57).  Enhanced up-regulation of MHC 
molecules containing chlamydial antigens may induce T cells to initiate both cell-
mediated and antibody immune responses against Chlamydia.  In addition to efficiently 
eliminating Chlamydia and presenting the peptides to T cells, Mϕ may also have an effect 
on chlamydial infection by inducing T cell death and perpetuating a persistent infection. 
DC are important for vaccine research because they are the critical links between 
innate and adaptive immunity (58).  Antigen presenting cells (APC) such as DC and Mϕ 
are able to phagocytose chlamydial EBs in the extracellular space or engulf infected cells 
harboring RB.  DC are known to be the quintessential APC.  Immature DC are highly 
phagocytic, and after internalization of pathogens, they degrade the components and 
present the peptides to T cells via MHC receptors.  This activates the T cells to initiate a 
cell-mediated and/or humoral immune response.  The types of cytokines produced and 
antigens processed by DC and presented to CD4
+
 T cells mediate the Th1/Th2 balance 
during a chlamydial infection (35). 
In summation, cell-mediated immunity that activates Mϕ, NK cells, NK T cells, 
neutrophils, and mediators such as IL-12 and IFN-γ is required for initial clearance. 
However, for protective immunity, both cell-mediated immunity and humoral immunity 
are needed, including antigen-specific T cells and antibodies that enhance phagocytosis 
and subsequent degradation and presentation of bacterial components by DC for a rapid 






2.4 Toll-like receptors (TLR) 
TLRs belong to the family of pathogen-associated molecular pattern recognition 
receptors (PRRs) and are vital components of the host’s immune system for sensing 
dangerous pathogens, and for initiating inflammatory and immune responses directed 
against these pathogens.  The mechanism of signal transduction through TLRs is well 
characterized (59-66).  There are two possible routes for mediation of signals received by 
TLRs depending on which of the two adapter molecules, myeloid differentiation factor 
88 (MyD88) and TIR-domain containing adapter-inducing interferon-β (TRIF), are 
involved.  The importance of MyD88 and TRIF lies in the finding that each leads to a 
distinct profile of immune mediators that in turn determine the phenotype of the cells that 
are primarily responsible for the development of adaptive immune responses (67-70).  
MyD88 represents a common adaptor protein required for signaling of all TLRs 
identified to date, with the exception of TLR3 (71).  TLR4 mediates through both the 
MyD88 and TRIF pathways, TLR3 signals through TRIF, and all the other TLRs mediate 
through MyD88 pathway.  TLRs as PRRs are pivotal for maximizing pathogen detection 
(72).  The TLR family includes a total of 11 receptors that are responsible for the 
recognition of highly conserved structural motifs that are essential for pathogen survival 
and are conserved across broad subclasses of microorganisms (73-74).  These conserved 
microbial structural motifs are referred to as pathogen-associated molecular patterns 
(PAMPs) (75-78).   
In this study we characterized the expression of MyD88 in response to our VCG 





2.5 Nuclear factor kappa B (NF-kB) 
Nuclear factor kappa B (NF-κB) is a family of transcription factors with important 
gene regulatory functions in inflammation (79).  This protein complex controls 
transcription of DNA and is found in almost all animal cell types (80-84).  NF-κB plays a 
key role in regulating the immune response to infection (κ light chains are critical 
components of immunoglobulins) and is responsible for cytokine production and cell 
survival (85-89). 
NF-κB is activated by known inducers which are highly variable and include 
reactive oxygen species (ROS), tumor necrosis factor alpha (TNFα), interleukin 1-beta 
(IL-1β), bacterial lipopolysaccharides (LPS), isoproterenol, cocaine, and ionizing 
radiation in response to harmful cellular stimuli (90).  
NF-κB is a major transcription factor that regulates genes responsible for both the 
innate and adaptive immune response. Upon activation of either the T- or B-cell receptor, 
NF-κB becomes activated through distinct signaling components. Through a cascade of 
phosphorylation events, the kinase complex is activated and NF-κB is able to enter the 
nucleus to upregulate genes involved in T-cell development, maturation, and proliferation 
(91). 
2.6 The roles of TLR and NF-kB during Chlamydia infection 
The involvement of Toll-like receptors (TLRs) has been suggested in various 
inflammatory and autoimmune diseases (67-69).  Binding of microbial ligands to TLRs 
elicit a sequence of molecular events that lead to activation of transcription factors such 





response.  TLR mediated activation of NF-κB requires phosphorylation of its p65 subunit 
through a second pathway that involves Rho-GTPase Rac1, phosphoinositide-3 kinase 
(PI3-K) and AKT (75-78, 92).   
TLR2 and TLR4 have been extensively studied and well characterized.  The 
expression of these PRR upon stimulation by Chlamydia or bacterial ghosts was 
investigated in this study.  The PAMPS that Toll-like receptors recognize include 
lipopolysaccharide (LPS), lipoprotein, nucleic acids and other phenotypic characteristics 
of bacterial pathogens.  
The ligand for TLR4, LPS, is a cell wall component mainly found in Gram-
negative bacteria.  Bacterial lipoproteins are recognized by TLR2, as well as the ligands 
peptidoglycan, lipoarabinomannan, porins and others, from not only bacteria, but viruses 
or parasites (93).  TLR2 and TLR4 are largely localized on the cell surface to recognize 
the aforementioned PAMPs (93). 
TLR2- and TLR4-mediated MyD88-dependent signaling pathways lead to 
activation of NF-κB and MAPK, inducing gene expression of type I IFN.   NF-κB also 
induces DNA transcription of IL-1β, tumor necrosis factor α (TNFα), B7, tissue factor 
etc. in response to infection by bacterial pathogens. 
2.7 Bacterial ghosts 
Expression of cloned PhiX174 gene E in Gram-negative bacteria results in lysis of 
the bacteria by formation of an E-specific transmembrane tunnel structure built through 
the cell envelope complex. Bacterial ghosts have been produced from a variety of 





Vibrio cholerae, Klebsiella pneumoniae, Actinobacillus pleuropneumoniae, Haemophilus 
influenzae, Pasteurella haemolytica, Pasteurella multocida, and Helicobacter pylori. 
Such ghosts are used as non-living candidate vaccines and represent an alternative to heat 
or chemically inactivated bacteria. In recombinant ghosts, foreign proteins can be 
inserted into the inner membrane prior to E-mediated lysis via specific N-, or C-, or N- 
and C-terminal anchor sequences. The export of proteins into the periplasmic space or the 
expression of recombinant S-layer proteins vastly extends the capacity of ghosts or 
recombinant ghosts as carriers of foreign epitopes or proteins. Oral, aerogenic or 
parenteral applications of (recombinant) ghosts in experimental animals induced specific 
humoral and cellular immune responses against bacterial and target components 
including protective mucosal immunity. The most relevant advantage of ghosts and 
recombinant bacterial ghosts as immunogens is that no inactivation procedures that 
denature relevant immunogenic determinants are employed in the production of ghosts 
used as vaccines or as carriers of relevant antigens. The inserted target antigens into the 
inner membrane or into S-layer proteins are not limited in size (94). 
Formation of a transmembrane tunnel structure with a diameter of 40-200 nm 
allows for the release of Gram-negative bacteria cytoplasmic material resulting in empty 
bacterial cells (ghosts) that retain all of the structural features of their outer envelope 
(95).  In this study, the transmembrane lysis mechanism of PhiX174 gene E was used to 
produce VCG which was investigated as a non-living material vaccine adjuvant in 






2.8 Bacterial ghosts as adjuvants 
Adjuvants may be used to nonspecifically or specifically, such as in the case of 
bacterial ghosts, to potentiate the immune response to target antigens.  Bacterial ghosts 
contain some well-known immune-stimulating compounds, such as LPS and 
peptidoglycan and specific receptor recognition properties of the envelope, contributing 
to effective uptake by macrophages and DC (96).  The endotoxicity of the LPS does not 
limit the use of bacterial ghosts as vaccine candidates.  Since LPSs and peptidoglycans 
are known adjuvants and bacterial uptake by macrophages is highly effective, 
immunization with low doses of bacterial ghosts will stimulate the innate immune system 
very efficiously, as seen in a protective mucosal response by aerosol application of ghosts 
in pigs, vibriocidal antibodies in mice, and humoral and cellular immunity to membrane 
anchored target proteins in rabbits and mice (97).  Additionally, it is known that most 
epitopes found to be protective following vaccination are located on the bacterial surface 
(97).  Comparable synthesis of inflammatory macrophage mediators, such as tumor 
necrosis factor (TNF)-α in the THP-1 cell line need a 100-fold higher dose of VCG than 
the corresponding amount of LPS (98-99).  The bacterial ghosts stimulate the activation 
of cellular Th1 immune responses by increased interleukin (IL)-12, IL-18 and TNF-α 
production (96).  Furthermore, the bacterial ghosts mediate the maturation of human DCs 
by decreasing the expression levels of CD83 and penetrate through matrigel-coated 
porous membrane (96).  In addition, an exposure of ghosts to DCs results in a marked 
increase in their ability to activate T-cells.  Thus, ghosts used as carriers of foreign 





2.9 Phagocytosis of bacterial ghosts 
Haslberger et al. investigated the activation of the antigen presenting cells by 
bacterial ghosts in more detail by studying the uptake of bacterial ghosts in dendritic 
porcine cells and RAW macrophages and the induction of inflammatory mediators or 
mediators directing the innate immune response in THP-1 human macrophage cell line.  
A rapid uptake of bacterial ghosts in macrophages within 10-30 minutes was confirmed 
by electron microscopy (fig. 2) (98).  DC are known to be phagocytic in specific 
immature states and Haslberger et al., observed significant uptake of bacterial ghosts 
within 2 hours.  Their data suggested that bacterial ghosts effectively stimulate 
monocytes and macrophages for the induction of Th1 directed immune responses and 
dendritic cells treated with bacterial ghosts may serve as a promising vehicle for active 
















Figure 2. Uptake of bacterial ghosts: Electron microscopy of mouse RAW macrophages.  Bacterial 
ghosts of E. coli O26:B6 have been added to the cell culture 20 min before.  Still intact cell walls as well as 
degraded cell walls of phagocytosed cells can be seen (A). Fluorescence microscopy of porcine dendritic 
cells which have been cultures with FITC labeled V cholerae ghosts.  Fluorescence can be seen centralized 
inside the cells (B) (98). 
  
2.10 Immune response elicited by bacterial ghosts 
Mayr et al. investigated the activation of antigen presenting cells (APC) by BG by 
studying the in vitro uptake of VCG and E. coli BG in dendritic cells and RAW 
macrophages and the induction of inflammatory mediators in the THP-1 human 





such as TNF-α in the THP-1 cell line was stimulated by a hundred-fold higher dose of 
VCG than the corresponding amount of free LPS with no toxic side effects from the 
administration of BG but with significant humoral immune responses.  Furthermore, the 
capability of BG to induce a T-cell-mediated immune response was studied following 
uptake of Actinobacillus pleuropneumoniae (APP) ghosts by primary APC in pigs.  
Specific T-cell responses were detected after in vitro re-stimulation of primed blood T 
cells with APP ghosts.  Additionally they investigated uptake of APP BG by DC and 
subsequent DC activation.  Following the internalization and processing of the antigens, 
increased expression of MHC class II molecules in APC was shown 12 h after their 







MATERIALS AND METHODS 
3.1 Chemicals and reagents 
Mammalian cell culture media were donated by Dr. Joseph Igietseme, Centers for 
Disease Control and Prevention. Bacterial cell culture media were purchased from Becton 
Dickinson.  Antibiotics (kanamycin and ampicillin; penicillin and streptomycin) were 
purchased from Sigma-Aldrich and Atlanta Biologicals, respectively. Agarose was 
purchased from Bio-Rad.  Isopropyl β-D-thiogalactoside (IPTG), 3-methyl benzoate 
(3MB), lipopolysaccharide from E. coli 026:B6, protease inhibitor, and concavalin A 
were purchased from Sigma-Aldrich. Pam3CSK4 TLR2 ligand was purchased from 
InvivoGen. QIAprep Spin Mini- and Midiprep Kits were purchased from Qiagen. 
Pathfinder Chlamydia Culture Confirmation System was purchased from Bio-Rad. Pierce 
BCA Protein Assay was purchased from ThermoScientific. BD OptEIA™ Set Human 
TNF ELISA was purchased from BD Biosciences. Sucrose-phosphate-glycerol (SPG) 
media was donated by Dr. Qing He, Morehouse School of Medicine.  Cycloheximide was 
donated by Dr. Joseph Igietseme, Centers for Disease Control and Prevention. 
Permount® was purchased from Fisher Scientific. Anti-human Toll-like receptor 4 
(CD284) and anti-human Toll-like receptor 2 (CD282) antibodies were purchased from 
eBioscience Affymetrix, San Diego.  MyD88 rabbit polycolonal antibody (385800), NF-





(656120) were purchased from Life Technologies, Grand Island, NY.  RNeasy
®
 Mini Kit 
was purchased from Qiagen Sciences, Maryland, USA. DAPI counter stain was donated 
by Dr. Periakaruppan Nagappan, Center for Cancer Research and Therapeutic 
Development, Clark Atlanta University. 
3.2 Mammalian and bacterial strains and growth mediums 
The monocytic leukemia cell line THP-1 (donated by Dr. Byron Ford, Morehouse 
School of Medicine and Dr. Joseph Igietseme, Centers for Disease Control and 
Prevention) was maintained in RPMI 1640 medium supplemented with 10% fetal bovine 
serum (FBS), 10 mM HEPES, 200 mM glutamine, 100 mM sodium pyruvate, 0.5% 
HEPES and penicillin/streptomycin (100 U/mL; 100 ug/mL) in a humidified atmosphere 
under 5% CO2, at 37°C. 
The cervical cancer cell line HeLa (donated by Dr. Joseph Igietseme, Centers for 
Disease Control and Prevention) was maintained in Minimum Essential Medium (MEM) 
Earle’s with 2mM L-glutamine, 10% heat-inactivated FBS, 1 mM sodium pyruvate, 0.5% 
fungizone, and 1.0% penicillin/streptomycin (100 U/mL; 100 ug/mL) in a humidified 
atmosphere under 5% CO2, at 37°C. 
Vibrio cholera (V588 or V912) from lab stocks were cultured in brain heart 
infusion (BHI) media supplemented with 100 ug/mL ampicillin and 25 ug/mL kanamycin 
and grown in suspension at 37°C while shaking at 125 rpm.  For induction of the lac 
promoter, isopropyl β-D-1-thiogalactopyranoside (IPTG) was added to growing cultures at 





E. coli (O26:B6) from lab stocks were cultured in Luria broth supplemented with 
0.2 ug/mL kanamycin and 0.2 ug/mL ampicillin and grown in suspension at 37°C while 
shaking at 250 rpm.  
3.3 Chlamydia trachomatis SPP 
Chlamydia trachomatis serotypes D,  E, and F were generated by propagating 
elementary bodies (EBs) in HeLa cells and the murine strain MoPN generated by 
propagating EBs in McCoy cells followed by purification of EBs over renografin 
gradients (generously donated by Dr. Joseph Igietseme, Centers for Disease Control and 
Prevention).  IFUs was provided on the packaging. 
3.4 Transformation of V. cholerae with chlamydial antigens  
V. cholerae (V588-pDKLO1) were maintained in BHI broth supplemented with 
kanamycin (25 ug/mL) at 37°C while shaking at 225 rpm to an A600 of 0.6 O.D.  After 
cell proliferation overnight, the cell pellet was harvested by centrifugation at 2900 rpm in 
two centrifuge tubes and prepared to make competent. The pellet was washed in sucrose 
electroporation buffer H (SEBH) (137 mM sucrose, 1 mM HEPES, 10% glycerol) 3x.  
After washing, the pellet was vortexed to loosen then, 100 uL aliquots of the competent 
cells were introduced to Eppendorf tubes and stored at -80°C.  To one of the aliquots, 
pKs-PmpD/PorB-FL was added and pulsed on a BioRad pulser for 4.8 secs at 200 Ω to 
transform the cells with the plasmid.  Transformants were inoculated into BHI and 
incubated for 1 h at 37°C while shaking.  After 1 h transformants were spread onto BHI 






3.5 Production of bacterial ghosts 
Production of the rVCG was carried out by gene E-mediated lysis.  Briefly, 
bacteria were maintained in BHI broth supplemented with ampicillin (100 ug/mL) and 
kanamycin (25 ug/mL) at 37°C while shaking at 200 rpm to mid-log phase. At this point, 
IPTG (2.5 mM) was added to the growing culture to induce the Lac operon for gene 
expression.  After 35 min of PmpD/PorB-FL induction, cell lysis was achieved by adding 
3MB (5 mM) to induce expression of gene E.  Production of the VCG was accomplished 
using the same protocol however, the broth did not require ampicillin.  When lysis was 
complete, cellular cultures were harvested by centrifugation and the pellet resuspended in 
a low ionic buffer then washed with cold PBS.  Harvested ghosts were resuspended in 
PBS then lyophilized and stored at room temperature until use. 
3.6 Protein gel electrophoresis and Western blots 
Three bacterial (V. cholerae) cell cultures containing pHs-PmpD/pDKLO1 were 
harvested and centrifuged at 4000 rpm for 15 min to pellet.  To prepare samples for 
polyacrylamide gel electrophoresis, cellular pellets were resuspended in 1 mL cold RIPA 
buffer to release whole cell protein.  Lysate was then transferred to 1.5 mL eppendorf 
tubes.   To ensure an efficient whole cell protein suspension, the cultures were sonicated 
for 2 bursts of 10 sec at ~30 W (watts).  Protein samples were diluted in 1X RIPA buffer 
at 1:1, 1:2 and 1:4 dilutions.  Samples were electrophoresed at 75 V for 3 h. 
Standard Western blotting procedure was used to confirm the identity of and 
quantify PmpD.  The primary and secondary antibodies used to probe PmpD were anti-





3.7 Infection of HeLa cell monolayer 
Chlamydia trachomatis serovar D (1.2 x 10
10
/mL IFUs) and MoPn (2.2 x 10
9
/mL 
IFUs) (donated by Dr. Joseph Igietseme, Centers for Disease Control and Prevention) 
were aliquot to a MOI of 3. HeLa cells (30 x 10
4
 cells/mL) maintained in MEM Earle’s 
Salts supplemented with 10% FBS and 1% pen/strep were seeded in a 24-well culture 
plate with cover slips and set in a 37°C, 5% CO2 jacketed incubator until confluent.  
Once confluent, the HeLa monolayer was treated with Serovar D or MoPn at a MOI of 3.  
Two wells were left untreated to serve as negative controls.  After treatment introduction, 
the plate was centrifuged at room temperature (RT) for 1 h at 2200 rpm, then 
immediately set in a 37°C, 5% CO2 jacketed incubator for 1 h.  The Chlamydia 
treatments were gently aspirated, and 1 mL of warm cycloheximide media was 
introduced and the plate was returned to 37°C, 5% CO2 jacketed incubator for 48 h. 
After 48 h, the cycloheximide media was gently aspirated.  Cells were gently 
washed 2x with PBS (6.0 - 7.5 pH). Infected cells were fixed with 1 mL of cold methanol 
(MeOH) and set in 4°C for 10 min.  After fixation the MeOH was aspirated and cells 
were washed 1x with PBS.  To stain inclusion bodies, Pathfinder
®
 Chlamydia Culture 
Confirmation System was introduced to each treated well and set in the dark for 2 h. 
After 2 h the plate was removed from the dark, and working in a germ-free darkened 
culture hood to protect the plate from intense light, the cover slips were removed from the 
wells and rinsed twice in dH2O then inverted onto a microscope slide containing 
Permount
®
 and viewed under fluorescent microscopy for detection and enumeration of 





3.8 Chlamydia-infected HeLa cell viability assay 
HeLa 229 (60 x 10
4
 cells/mL), endocervical epithelial cells, were infected with 
Chlamydia elementary bodies of strain MoPn or serovar F, then cultured in the 
supernatant from THP-1 macrophages pulsed by murine splenocytes and VCG.  HeLa 
cell monolayers were infected with MoPn or serovar F at an MOI of 5.  Two HeLa cell 
monolayers were pre-treated with DEAE-dextran (45 ug/mL) for 15 min at 37˚C prior to 
infection.  Chlamydia infected HeLa cell monolayers were incubated overnight.  4 h post 
infection (PI) HeLa monolayers were observed by phase microscopy for cytotoxicity.  
HeLa cells were identified for rounding, detachment and lysis vs. uninfected controls.  
The following morning CT-infected media was removed by pipet and cell monolayers 
were washed 3x with MEM Earle’s Salts media.  1 mL of conditioned media was 
introduced to each CT-infected HeLa cell monolayer and returned to the humidified 
incubator under 37˚C, 5% CO2 for 24 h.  MEM Earle’s Salts media was added to 
uninfected HeLa cell monolayers, serving as our negative control.  Cell viability was 
assayed by microscopy and counting cells using a cellometer (Nexcelom). 
3.9 Determination of cytotoxicity of VCG on THP-1 cells 
THP-1 monocytes (Mn) were maintained in RPMI 1640 medium supplemented 
with 10% FBS, 200 mM glutamine, 100mM sodium pyruvate, 1% 
penicillin/streptomycin (100 U/mL; 100ug/mL), and 0.5% HEPES (complete medium) in 
a humidified atmosphere under 5% CO2, at 37°C overnight.  The following day 3 mL 
aliquots of THP-1 Mn (4.2 x 10
7
 cells/mL) were seeded in a 6-well plate then pulsed in a 





ug/mL for 3 h.  LPS (1 ug/mL) and RPMI 1640 served as positive and negative controls, 
respectively.  After this, treated cellular pellets were collected by centrifugation at 1500 
rpm for 10 min at 4°C, then resuspended in VCG-free medium and returned to the 
incubator overnight.  The following day, 20 uL of each culture was aliquot into a 
cellometer chamber slide and counted using a Cellometer (Nexcelom). 
3.10 Dose and kinetic experiments  
THP-1 monocytes (Mn) were maintained in RPMI 1640 medium supplemented 
with 10% FBS, 200 mM glutamine, 100mM sodium pyruvate, 1% 
penicillin/streptomycin (100 U/mL; 100ug/mL), and 0.5% HEPES (complete medium) in 
a humidified atmosphere under 5% CO2,  at 37°C overnight.  To measure the secretion 
levels of tumor necrosis factor (TNF) elicited by VCG, THP-1 Mn were treated with 
VCG at 20, 15, 10, 5, or 1 ug/mL for 24, 48, or 72 h in a humidified atmosphere under 
5% CO2, at 37°C in an initial experiment.  Then, THP-1 Mn were treated with VCG at 
10, 5, or 1 ug/mL for 6, 12, or 18 h.  THP-1 Mn incubated in the presence of RPMI 1640 
complete media alone or E. coli O26:B6 LPS (1 ug/mL) served as negative and positive 
controls, respectively.  The level of TNF secreted was determined by TNF ELISA (BD 
Biosciences).  
3.11 Cytokine secretion by THP-1 Mn or Mϕ following pulse by VCG  
THP-1 monocytes (Mn) were maintained in RPMI 1640 supplemented with 10% 
FBS, 200 mM glutamine, 100mM sodium pyruvate, 1% penicillin/streptomycin (100 
U/mL; 100ug/mL), and 0.5% HEPES (complete medium) in a humidified atmosphere 





macrophages (Mϕ) by treatment with 160 nM PMA (phorbol 12-myristate 13-acetate) for 
1 h.  After 1 h the activated monocytes were pelleted by centrifugation at 1500 rpm for 10 
min to remove PMA treatment then resuspended in PMA-free complete media. 1 mL 
PMA-free cell culture aliquots were put into ten wells of a 24-well plate.  Mn cellular 
culture was aliquot (1 mL) into ten wells of the same 24-well plate and returned to the 
incubator overnight (o/n).  The next day THP-1 Mn (2.7 x 10
6
 cells/mL) and Mϕ (1.2 x 
10
6
 cells/mL) were treated with VCG (10 ug/mL), VCG (10 ug/mL) and IL-10 (5 
ug/mL), or LPS (1 ug/mL).  LPS served as a positive control; RPMI 1640 complete 
medium, served as a negative control.  IL-10 was co-pulsed with VCG as a negative 
control to inflammatory cytokine secretion.    Mn and Mϕ were pulsed for 24 h in a 
humidified atmosphere under 5% CO2, at 37°C.  Following the stimulation period the 
contents of each well were carefully transferred to its own 1.5 mL Eppendorf tube and 
centrifuged at 1500 rpm for 10 min at 4°C to collect the cellular supernatant (soups).  
Soups were kept at -20°C until assayed by Multiplex technology (Quansys Biosciences, 
Logan, UT).   
3.12 Isolation, culture and activation of murine splenocytes 
Spleens from five 14 week old C57BL/6 female nude mice were removed and 
processed to isolate murine splenocytes.  Mice were euthanized by CO2 suffocation.  
Spleens were removed and placed in chilled PBS with 0.5% FBS.  To isolate murine 
splenocytes, spleens (one at a time, using a new strainer each time) were placed in a 100 
um cell strainer placed atop a 50 mL centrifuge tube containing 5 mL RPMI 1640 





with a rubber policeman until most of the tissue had passed through.  The strainer and 
policeman were then rinsed with 1 mL RPMI 1640 complete media to ensure all cells 
passed through the strainer.  Once all the spleens were processed, the cellular suspension 
was collected by pipet and passed through a 70 um cell strainer atop a 50 mL centrifuge 
tube.  The cellular suspension was again collected by pipet and transferred to a 15 mL 
centrifuge tube and centrifuged at 90g for 5 mins to collect the cellular pellet.  Cellular 
pellet was then resuspended in RPMI 1640 complete medium, placed in a culture flask 
and set in a humidified incubator under 37˚C, 5% CO2 for 2.5 days.  To activate murine 
splenocytes, 1 uL PMA (160 nM) plus 10 uL concavalin A (1 %) was added to 10 mL of 
murine splenocytes (1.2 x 10
6
 cells/mL) and returned to humidified incubator under 37˚C, 
5% CO2 for 24 h.   
3.13 Co-culture of activated THP-1 Mn or Mϕ with murine splenocytes 
     [Activated] murine splenocytes culture was removed from incubation and counted 
using Trypan blue exclusion with a hemacytometer. For efficient co-culture with THP-1 
Mn or activated Mϕ, 225 uL of murine splenocytes (1.6 x 10
6
 cells/mL) (8:1) were added 
to a 96-well plate that already contained THP-1 Mn or activated Mϕ designated treatment 
wells.  Plate was returned to the humidified incubator under 37˚C, 5% CO2 for 48 h.  
After 48 h co-cultures and controls were carefully removed by pipet, put into 1.5 mL 
eppendorf tubes and centrifuged at 500 rpm for 10 mins to collect cellular supernatants.  
Cellular supernatants were introduced with 1 – 2 uL protease inhibitors and stored in -






3.14 Multiplex assay 
Multiplex assay was contracted out to Quansys Bioscience, Logan, UT.  All 
samples were tested for IL-1α, IL-1β, IL-2, IL-4, IL-6, IL-10, IL-12p70, IL-17, IL-23, 
IFNγ, and TNFα by Quansys Biosciences (Logan, UT) Q-Plex Array
TM
 kits for human 
cytokines.  Samples were thawed on ice and diluted into Quansys Human Sample 
Dilution Buffer prior to loading into preparatory polypropylene low-binding 96-well 
plates. Standard ELISA incubation steps apply such as initial sample incubation, 
washing, secondary antibody incubation, washing, incubation with the label and 
measurement are involved. The label and reporting system used in a Q-Plex Array
TM
 is 
chemiluminescent.  The total protein concentration was determined via absorbance at 280 
nm and an extinction coefficient of 1 using a Nanodrop ND-1000 spectrophotometer 
(Thermo Scientific, Wilmington DE). 
3.15 Immunofluorescence  
THP-1 Mϕ (11 x 10
4
 cells/mL) were seeded onto an 8-well glass Chamber 
Slide™ (Lab-Tek
®
) then introduced with 4% formalin for 15 min in a humidified 
incubator under 5% CO2, at 37˚C to fix the monolayer.  After 15 min, the fixative was 
carefully removed by pipet, and the cell monolayers were washed 3x with PBS for 5 min 
each.  To probe for TLR expression, anti-human Toll-like receptor 4 (CD284) (1 ug) or 
anti-human Toll-like receptor 2 (CD282) (1 ug) (eBioscience Affymetrix, San Diego) 
antibody was added at a concentration of 1:100 or 1:200 and incubated in a humidified 
incubator under 5% CO2, at 37˚C for 4 – 5 h. After incubation with the respective 





3x with PBS for 5 min each.  DAPI counterstaining was introduced to the monolayers 
(for nuclei staining), covered with a coverslip and sealed with clear nail polish to secure 
for viewing under fluorescent microscopy. 
THP-1 Mn (1 x 10
6
 cells/mL), maintained in RPMI 1640 complete media, were 
seeded into a 24-well plate and pulsed by VCG (10 ug/mL), LPS (1 ug/mL), or EB (MOI 
2.5).  RPMI 1640 complete media served as a negative control, and LPS and EB served 
as positive controls.  THP-1 Mn were pulsed for 6 h in a humidified incubator under 5% 
CO2, at 37°C.  After the treatment period, the contents of each well was transferred to its 
own 1.5 mL Eppendorf tube and centrifuged at 1500 rpm for 10 min to collect the 
cellular pellet.  Each pellet was resuspended in 1 mL RPMI 1640 complete media.  50 uL 
of each was introduced to an 8-well glass Chamber Slide™ (Lab-Tek
®
) and set in the 
incubator for 5 min.  Then, 100 uL of 4% formalin fixative was added to each well and 
returned to the incubator for 15 min.  After 15 min, the fixative was removed by 
aspiration and each well washed 3x with PBS for 5 min each.  Then, under dimly lit 
conditions, 1 ug CD282 (TLR2) AlexaFluor
®
 488 antibody or 1 ug CD284 (TLR4) 
AlexaFluor
®
 488 antibody (Affymetrix  eBiosciences) was introduced to each designated 
sample well and returned to the incubator for 2 h.  After 2 h, the antibody was washed off 
3x with PBS for 5 min each.  DAPI counterstain was introduced to the slide (for nuclei 
staining) and covered with a coverslip then sealed with clear nail polish and set in the 







3.16 Characterization of MyD88 and NF-kappa B  
THP-1 Mn were maintained in RPMI 1640 medium supplemented with 10% FBS, 
200 mM glutamine, 100mM sodium pyruvate, 1% penicillin/streptomycin (100 U/mL; 
100ug/mL), and 0.5% HEPES (complete medium) in a humidified atmosphere under 5% 
CO2, at 37°C overnight.  The following day, to induce differentiation into adherent Mϕ, 
the culture was treated with PMA (160 nM) for 1 h.  After 1 h, the cellular pellet was 
collected by centrifugation at 1500 rpm for 10 min to remove PMA treated media.  The 
pellet was resuspended in 1 mL PMA-free media then brought to a final volume of 25 
mL.  1 mL (5.24 x 10
6
 cells/mL) aliquots of the activated Mn cell culture were seeded 
into the wells of a 24-well plate and returned to the incubator for 8 h. After 8 h, activated 
Mϕ were pulsed with VCG (10 ug/mL), Pam3CSK4 (250 ng/mL), a TLR2 agonist, MoPn 
elementary bodies (MOI 10), LPS (1 ug/mL), or RPMI 1640, which served as a negative 
control, for 4 – 6 h in a humidified atmosphere under 5% CO2, at 37°C.  After the 
treatment period the cellular pellet was collected by centrifugation and prepared for 
protein concentration analysis using Pierce BCA Protein Assay (ThermoScientific) 
following manufacturer’s instructions.  Briefly, cellular pellet was washed 3x in PBS. 
Then to lyse the cells, the pellet was resuspended in lysis buffer (RIPA buffer, PMSF, 
protease inhibitor, β-mercaptoethanol, and DTT), vortexed for 30 sec, set in -80°C for 10 
min, then set on ice to thaw.  This was repeated twice.  After, the lysate was centrifuged 
at 4°C at 10,000 rpm for 5 mins.  Then the lysate was diluted 1:8 (v/v) with working 
reagent, incubated at 37°C for 30 min, cooled at room temperature then protein 





enough protein to prepare the samples for Western blot analysis and characterization of 
NF-kB transcription factor or MyD88 adaptor protein.  Blot was developed by 
chemiluminescence and viewed using the LAS4000 Imager. 
3.17 Statistical analysis 
Where applicable, data were analyzed by a paired Student’s t-test or ANOVA 
using GraphPad Prism software. The level of significance was judged at p < 0.05. 





             CHAPTER IV 
RESULTS 
4.1 Transformation of Vibrio cholerae 
Competent Vibrio cholerae (V588-pDKLO1) cells were successfully transformed 
with pKs-PmpD/PorB-FL.  Transformation of plasmid DNA into wild type Vibrio 
cholerae strains was possible by electroporation.  Transformants were plated on BHI agar 
and LB agar and incubated at 37°C overnight.  The following morning all cultures had 
colony growth relative to the volume of transformants plated. 
4.2 PhiX174 gene E-mediated lysis of V. cholerae and construction of the vaccine 
vector 
 
The protein E-mediated lysis system is derived from the E. coli-specific 
bacteriophage PhiX174.  It exerts its lytic function by the fusion of inner and outer 
membranes and transmembrane tunnel formation.  After controlled expression of 
subcloned gene E during the exponential growth phase of the bacteria, which includes all 
cell surface structures and appendices, none of the bacteria morphology is affected by the 
lysis event and the peptidoglycan is not degraded (101).  The lysed bacteria (ghosts) 









Figure 3. Protein E-mediated lysis of Gram-negative bacteria.  Bacterial ghost system. Inducible 
expression of gene E causes the fusion of inner and outer membranes of the bacterial cells and forms an 
intermembrane tunnel.  The empty BG envelope is devoid of cytoplasmic content, whereas the inner and 
outer membrane structures including LPS and peptidoglycan are preserved and remain intact (104). 
 
Vibrio cholerae V588 harboring the membrane targeting plasmid pKs was co-
transformed with the lysis plasmid pDKLO1.  Cultures were normally grown at 28°C.  
Transcription of gene E from plasmid pDKLO1 was directed by the activity of thermos-
sensitive repressor coded on the plasmid.  Temperature increase of exponentially growing 
Vibrio cholerae to 42°C led to rapid de-repression and protein E induction.  The extent 
and rate of lysis was quantified from the decrease in turbidity/unit of time and monitored 
by measuring the absorbance of the lysing culture at 600 nm (fig. 4).  At the end of lysis, 
the lysed cells (VCG) were harvested by centrifugation (330g, 4°C, 10 min, Beckman 
Coulter GS-6R), washed 3x in 50 mL ice-cold PBS, and resuspended in 2 mL ice-cold 
PBS/sorbitol.  For long-term storage, VCG were lyophilized and kept at room 






Figure 4. Production of Vibio cholerae ghosts.  V. cholerae strain V588 were transformed with the lysis 
plasmid pDKLO1. The transformed bacterial cells were grown at 37°C in brain heart infusion broth 
containing Kanamycin (25 ug/mL) to an optical density of 1.0 (A600).  Cell lysis was achieved by the 
addition of 3-methyl-benzoate (5 mM) to induce gene E expression (12). 
 
 
Figure 5. Lyophilized Vibrio cholerae ghosts. For long-term storage, lyophilized VCG are kept at room 
temperature.  
 
4.3 Characterization of Polymorphic Membrane Protein D (PmpD) 
Western blot analysis of PmpD chlamydial protein (fig. 6) with monoclonal anti-































IPTG induction in the VCG.  The total cellular protein of V. cholerae V588 cultures 
transformed with the expression plasmid containing PmpD revealed the appearance of 
PmpD-specific bands (fig. 6) visualized by use of anti-PmpD monoclonal antibody, HRP-









Figure 6. Western blot of Chlamydial Polymorphic Membrane Protein D (PmpD). Characterization of 
PmpD,, a  67 kDa protein, expression on V. cholerae bacterial ghost. 
 
4.4 Immunogenicity of Vibrio cholerae ghost vaccine vector 
TNF ELISA 
VCG, used as an adjuvant, will stimulate a signaling pathway and elicit its own 
immune response.  As an initial experiment to determine immunogenicity, TNFα 
secretion was measured by Human TNF ELISA set (BD OptEIA™).  TNF is one of a few 
cytokines that stimulate the acute phase reaction following infection by pathogens. Other 
acute phase cytokines include IL-1β, IL-4, IL-6, and IL-8. THP-1 Mn were pulsed by 
VCG at varying concentrations (20, 15, 10, 5 or 1 ug/mL) for 1 – 3 days.  After 24 h TNF 
secretion was only slightly developing (fig. 7). Leading us to believe 1) the dosage was 
insufficient; or 2) the kinetics for VCG takes longer. TNF secretion from the positive 







was due to experimental error.  From these results we extended our time-course to 
include 48 h and 72 h stimulation of THP-1 cells with only 10 or 15 ug/mL VCG since 
these two dosages elicited significant initial TNF secretion. 
 
Figure 7. Graph of tumor necrosis factor alpha (TNFα) secretion (24 h). THP-1 monocytes (Mn) were 
pulsed by VCG at various dosages and lengths of time to determine the optimal dose and pulse duration for 
TNF secretion to peak. This initial data was inconclusive. 
 
We have seen ghosts “clump” together when resuspended in cell culture medium 
in preparation for stimulating cells.  We speculate that this results in the VCG particles 
being too large for cell surface receptors to bind and engulf.  As such, going forward we 
prepared the VCG stock solution in 1:1 PBS:FBS then vortexed briefly to distribute 






































concentration of the FBS protein significantly reduced clumping, leaving ghosts that the 
cell could more efficiently uptake.  TNF secretion after 24, 48 and 72 h was measured 
using human TNF ELISA set (fig. 8a – c).  After 24 h and 48 h stimulation of THP-1 
cells with 10 or 15 ug/mL VCG, TNF secretion was 681 pg/mL (figs. 8a & 8b).  After 72 
h stimulation of THP-1 cells with 10 or 15 ug/mL VCG, TNF secretion was 242 pg/mL 
and 256 pg/mL, respectively (fig. 8c).   24 h secretion of TNF by LPS (positive control) 
treated THP-1 Mn was lower compared to THP-1 Mn treated by ghosts (at 10 or 15 
ug/mL). This could indicate that soluble LPS (1 ug/mL) is toxic to the cells at this 
concentration and/or time-course therefore, leading to a reduction in TNF concentration 













Figure 8a-c. TNF secretion preliminary data.  Following 24 h and 48 h pulse of THP-1 Mn by VCG (15 
ug/mL or 10 ug/mL), secretion of the proinflammatory cytokine TNFα was 681 pg/mL (a & b).  TNFα 
secretion after 3 days was significantly less (c). LPS (1 ug/mL) serves as the positive control.  RPMI 1640 














































Figure 8a-c. TNF secretion preliminary data.  Following 24 h and 48 h pulse of THP-1 Mn by VCG (15 
ug/mL or 10 ug/mL), secretion of the proinflammatory cytokine TNFα was 681 pg/mL (a & b).  TNFα 
secretion after 3 days was significantly less (c). LPS (1 ug/mL) serves as the positive control.  RPMI 1640 
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Figure 8a-c. TNF secretion preliminary data.  Following 24 h and 48 h pulse of THP-1 Mn by VCG (15 
ug/mL or 10 ug/mL), secretion of the proinflammatory cytokine TNFα was 681 pg/mL (a & b).  TNFα 
secretion after 3 days was significantly less (c). LPS (1 ug/mL) serves as the positive control.  RPMI 1640 
complete medium served as the negative (neg) control. 
 
Following these results we hypothesized that that optimal secretion of the 
proinflammatory cytokine TNF-alpha by THP-1 cells pulsed with VCG occurs <24h. 
Therefore, THP-1 monocytes were pulsed with VCG (1, 5 or 10 ug/mL) for 6, 12 and 18 
h and the concentration of TNF secretion was measured (fig. 9) by ELISA.  Our results 
indicated that the optimal dose of VCG is 10 ug/mL and stimulation of THP-1 Mn for 
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our hypothesis that optimal secretion of the proinflammatory cytokine TNF-alpha by 
THP-1 cells pulsed with VCG is <24h. 
 
Figure 9. TNF peak production. THP-1 Mn were pulsed with VCG (1, 5, or 10 ug/mL) for 6, 12 or 18 
h.The optimal dosage of VCG was determined to be 10 ug/mL to elicit peak production of TNF. Optimal 
pulse time is between 4 - 6 h.  These conditions were used throughout the research to determine immune 
responses elicited by VCG. 
 
Cytokine secretion by THP-1 cells primed with IL-10 is down-regulated 
The identification and characterization of cytokines secreted from cells involved 
in innate immunity can broaden our understanding of immune cell function.  The human 
myelomonocytic cell line, THP-1, has two morphologies – monocytes, which grow in 
suspension and monocyted-derived macrophages which are adherent.   The two THP-1 
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(5 ug/mL), an anti-inflammatory cytokine.  Cellular supernatants were assayed via 
Quansys Biosystems Q-Plex Array
TM
 technology; a traditional ELISA technology 
performed in micro-scale and multiplexed allowing for the simultaneous measurement 
and detection of multiple proteins.   
Th1-type cytokine secretion of IL-21p70, IL-15, IL-23, IFNγ, and TNFα by THP-
1 Mn was greater than secretion of the same cytokines by THP-1 Mϕ (figs. 10a and 10b), 
except for IL-1β secretion which was twice as high by THP-1 Mϕ (fig. 11).  When 
primed by IL-10, cytokine secretion by THP-1 Mn > THP-1 Mϕ (figs. 12a and 12b), 
except for IL-1β (fig. 11) and IL-12p70.  TNFα secretion was higher by THP-1 Mn than 


















Figure 10. T helper 1-type cytokine secretion by THP-1 monocytes or macrophages.  Th1-type 
cytokine secretion by Mn (a) was greater than by Mϕ (b) when pulsed by VCG.  Multiplex assay was 












































































Figure 11. IL-1β secretion. IL-1β secretion under all treatment conditions.  Secretion by THP-1 Mϕ was 
double that by Mn following pulse with VCG (10 ug/mL).  Multiplex assay was employed to determine 
analyte concentration.  IL-1β is an acute phase cytokine that plays a role in mediating the inflammatory 















Figure 12. THP-1 Mn or Mϕ primed with IL-10 and pulsed with VCG (10 ug/mL). Th1-type 
cytokine secretion by Mn (a) was greater than by Mϕ (b) when the cells were primed with IL-10.  
The only exceptions were secretion by IL-1β and IL-12p70.  Multiplex assay was employed to 
determine analyte concentration.  
 
Th2-type cytokine secretion of IL-4, IL-6, IL-10, and IL-13 varied based on cell 









































































differed by only 0.4 pg/mL. THP-1 Mϕ secreted IL-6 nearly three times that by THP-1 
Mn.  IL-10 secretion by THP-1 Mn was 51.1 pg/mL, whereas Mϕ secretion of this 
cytokine was negligible (figs. 13a and 13b).  Secretion of IL-10 by cells primed with IL-
10 was significant (fig. 14). THP-1 Mϕ secretion of IL-10 was higher (27203 pg/mL) vs. 
THP-1 Mn secretion of IL-10 (19730 pg/mL) (figs. 14a and 14b, respectively).  This 





















Figure 13. T helper 2-type cytokine secretion by THP-1 monocytes or macrophages. Secretion of IL-6 
was modest by both Mn or MΦ.  Secretion of IL-10 by Mn was 51 pg/mL (a) but negligible by Mϕ (b) 
likely due to the phenotype of the cell morphologies. Mn express the marker for IL-10; MΦ do not express 












































































Figure 14. IL-10 concentration by IL-10 primed VCG-pulsed THP-1 Mn or Mϕ.  IL-10 concentration 
is that which was used to pulse the cells, not secretion by Mn (a) or Mϕ (b).  Multiplex assay was employed 
to determine analyte concentration. 
 
 
Th1-type (IFNγ and TNFα) and Th2-type (IL-4 and IL-10) cytokines is 













































































Figure 15. T helper 1 and T helper 2 cytokines.   Th1 (IFNγ and TNFα) and Th2 (IL-4 and IL-10) 
cytokines mean concentration following VCG-pulse of THP-1 monocytes or macrophages.  When IL-10 
was added to treatment, TNFα secretion was attenuated.  Conversely, IL-10 concentration was a result of 
that added to the culture.  Multiplex assay was employed to determine analyte concentration. 
 
Cytokine secretion following co-pulse Murine splenocytes and THP-1 Mn or THP-1 Mϕ  
THP-1 Mn or Mϕ were pulsed by VCG (10 ug/mL) and Chlamydia EBs serotype 
F (MOI 5), then co-cultured with activated murine splenocytes (isolated from 14 week 
old C57BL/6 female nude mice).  The cellular supernatants were assayed for splenocytes 
cytokine production by Quansys Biosciences (Logan, UT).   
THP-1 cells have been shown to have antigen presentation character (105) 
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THP-1 monocytes and macrophages, 23 markers uniquely expressed on THP-1 
monocytes, and 20 markers uniquely expressed on THP-1 macrophages (106).  Upon 
stimulation with cytokines, THP-1 cells have been demonstrated to acquire dendritic cells 
(DC) properties (107-109).   
Multiplex assay was contracted out to Quansys Bioscience, Logan, UT.  The 
samples were tested for IL-1α, IL-1β, IL-2, IL-4, IL-6, IL-10, IL-12p70, IL-17, IL-23, 
IFNγ, and TNFα by Quansys Biosciences (Logan, UT) Q-Plex Array
TM
 kits for human 
cytokines.  The total protein concentration for splenocytes cytokine production was 
determined via absorbance at 280 nm and an extinction coefficient of 1 using a Nanodrop 
ND-1000 spectrophotometer (Thermo Scientific, Wilmington DE).    
T helper 1-type (IL-1α, IL-1β, IL-12p70, IFNγ and TNFα) (figs. 16a and 16b) or 
Th2-type (IL-4, IL-6, IL-10 and IL-17) (figs. 16c and 16d) cytokines fluctuated 
depending upon the morphology of the presenter (Mn or Mϕ).  IFNγ, a cytokine 
previously reported [by our lab] as having high titer in Chlamydia infected mice vaginal 
washes (3), was secreted at a modest level by splenocytes when co-cultured with VCG-
pulsed or EB-pulsed THP-1 Mn (fig. 16a).  The same was true for VCG+EB-pulsed or 
EB-pulsed Mϕ (fig. 16b). IL-1α was secreted by splenocytes at the same level when co-

























































































Figure 16. T helper 1-type and T helper 2-type cytokines.  Th1-type cytokine, IFNγ, was only 
measureable when Mn were pulsed with EB or VCG.  But when EB and VCG were in treatment together, 
secretion of IFNγ was negligible.  We expected IFNγ secretion to increase (a1-a4).  Mϕ secretion of Th1-
type cytokines was much more robust (b1-b4). Th2 cytokine, IL-6 secretion was constant in all treatment 
conditions with Mn (c1-c4).  Th2-type cytokines IL-6, IL-10 and IL-17 secretion fluctuated depending on 



































































































































































Figure 16. T helper 1-type and T helper 2-type cytokines.  Th1-type cytokine, IFNγ, was only 
measureable when Mn were pulsed with EB or VCG.  But when EB and VCG were in treatment together, 
secretion of IFNγ was negligible.  We expected IFNγ secretion to increase (a1-a4).  Mϕ secretion of Th1-
type cytokines was much more robust (b1-b4). Th2 cytokine, IL-6 secretion was constant in all treatment 
conditions with Mn (c1-c4).  Th2-type cytokines IL-6, IL-10 and IL-17 secretion fluctuated depending on 
the treatment conditions (d1-d4). 
 
IL-4 and IL-6 showed measureable secretion by monocytes in all treatment 

















































































VCG/EBs/splenocytes or EBs/splenocytes - ~60 pg/mL.  Secretion of IL-6 was only ~30 
pg/mL when Mn were co-pulsed by VCG/splenocytes (fig. 16c).  IL-6, IL-10, and IL-17 
showed measureable secretion by macrophages under all treatment conditions (fig. 16d).  
IL-6 secretion was about the same (~80 pg/mL) when Mϕ were co-pulsed with 
VCG/EBs/splenocytes or EBs/splenocytes.  IL-10 secretion was attenuated when EBs 
were in treatment, averaging 15 pg/mL vs. 50 pg/mL when not in treatment.  IL-17 





























































































Figure 16. T helper 1-type and T helper 2-type cytokines.  Th1-type cytokine, IFNγ, was only 
measureable when Mn were pulsed with EB or VCG.  But when EB and VCG were in treatment together, 
secretion of IFNγ was negligible.  We expected IFNγ secretion to increase (a1-a4).  Mϕ secretion of Th1-
type cytokines was much more robust (b1-b4). Th2 cytokine, IL-6 secretion was constant in all treatment 
conditions with Mn (c1-c4).  Th2-type cytokines IL-6, IL-10 and IL-17 secretion fluctuated depending on 



































































































































































Figure 16. T helper 1-type and T helper 2-type cytokines.  Th1-type cytokine, IFNγ, was only 
measureable when Mn were pulsed with EB or VCG.  But when EB and VCG were in treatment together, 
secretion of IFNγ was negligible.  We expected IFNγ secretion to increase (a1-a4).  Mϕ secretion of Th1-
type cytokines was much more robust (b1-b4). Th2 cytokine, IL-6 secretion was constant in all treatment 
conditions with Mn (c1-c4).  Th2-type cytokines IL-6, IL-10 and IL-17 secretion fluctuated depending on 

















































































4.5 Endotoxicity of Vibrio cholerae ghost vaccine vector  
 
To confirm that the bacterial ghost system, specifically V. cholerae ghost, is a 
viable, non-toxic therapy for antigen and drug delivery, THP-1 monocytes were pulsed 
for 3 h with varying concentrations (20 ug/mL, 15 ug/mL, 10 ug/mL, 5 ug/mL or 1 
ug/mL) of VCG; LPS (1 ug/mL) or RPMI 1640 complete media serving as a positive or 
negative controls, respectively (fig. 17).  Cells continued to proliferate normally 
following pulse with VCG, indicating that our vector is not toxic to the cells at any 
dosage.  Proliferation overnight was as much as 60% (20 ug/mL VCG). 
 
Figure 17. VCG are not toxic to THP-1 cells.  THP-1 monocytes pulsed by various concentrations of 







4.6 Enumeration of Chlamydia inclusion forming units (IFUs) 
HeLa cells were treated with two different strains of chlamydia in an effort to 
determine if either was more toxigenic than the other and to detect and enumerate 
inclusion forming units under fluorescent microscopy (fig. 18).  The human strain of 
Chlamydia trachomatis, serovar D, developed fewer IFUs (fig. 18b).  Conversely, MoPn 
(Chlamydia pneumonia), developed more IFUs (fig. 18c) at equitable MOI.  This result 
indicates that the toxigenic effect of MoPn may be greater (fig. 19). 
 Figure 18.  Immunofluorescence of HeLa infectivity assay.  Uninfected HeLa (a), serovar D infected (b) 











       






Figure 19. Quantitative enumeration of chlamydia inclusion forming units (IFUs).  HeLa cells were 
infected with Chlamydia trachomatis serovar D (MOI 10) or Chlamydia pneunomiae (MoPn) (MOI 10).  
After infectivity, inclusion forming units were enumerated.  Infectivity by MoPn was 34.2% > serovar D. 
 
The [serovar D] infected HeLa cells appeared more distressed with marked cell 
rounding (figs. 18b and 18c), morphological changes not observed in untreated HeLa 
cells which were elongated with sharp points (fig. 18a).  MoPn and Serovar D initiated 
entry and successfully infected the cells, forming Incs.  MoPn had higher levels of 
infection at the same MOI than serovar D based on the physical counts and 
immunofluorescent microscopy (figs. 18b and 18c).  99% of the cells treated with serovar 
D or MoPn were successfully infected and is quantitatively illustrated in figure 19. HeLa 
cells treated with serovar D had 1.19 x 10
3
 IFUs/mL; HeLa cells treated with MoPn had 
3.48 x 10
3
























4.7 Cytokines secreted by murine splenocytes are toxic to Chlamydia-infected HeLa 
cells 
 
To determine if the factors secreted by murine splenocytes co-cultured with VCG-
pulsed THP-1 macrophages were toxic to Chlamydia-infected HeLa cells, CT-infected 
HeLa monolayers were cultured in the supernatants from the culture-stimulated THP-1 
cells.  The CT-infected HeLa cells were visibly stressed 4 h post infection (PI) (figs. 20b-
e) vs. uninfected (fig. 20a) as observed by phase microscopy.  Cell morphology was 
rounded or detached in stressed cells.  Two of the monolayers (figs. 20c-e) were 
pretreated with DEAE-dextran to induce cell sensitization (103).  This was done to 
compare the efficiency of EB uptake by the HeLa cells.  The toxic effect of the factors 
contained in the supernatants from the culture-stimulated THP-1 cells was evident 8 h 
post-culture (fig. 21) and consistent among both Chlamydia strains.  The toxigenic effect 
of the factors was evidenced by cell viability of uninfected vs. infected cells (DEAE-
treated or not) (fig. 22) by counting post-treatment-culture using a cellometer 
(Nexcelom).  MoPn-infected HeLa cell viability decreased by 99.65%, whereas serovar 
F-infected HeLa cell viability decreased by 92.5% after 24 h.  DEAE-dextran (DD) 
pretreated MoPn-infected HeLa cells were 10% viable vs. DD-pretreated serovar F-








Figure 20. Chlamydia infected HeLa cell monolayers 4 h post infection (PI). Uninfected (a), DEAE-
dextran pretreated serovar F-infected (b), Serovar F-infected (c), DEAE-dextran pretreated MoPn-infected 
(d) MoPn-infected (e).  HeLa cells exhibited stress (“ballooning”) following infection by Chlamydia 





Figure 21. Chlamydia infected HeLa cell monolayers after 8 h culture in conditioned media. Effects of 
immunostimulatory factors secreted by VCG-pulsed THP-1 cells was evidenced by cell morphological 
alterations with marked cell rounding (in serotype F infected) characterized by a distinct “ballooning” 






Figure 22. HeLa cell viability following culture in conditioned media.  The toxigenic effect of 
immunostimulatory factors contained in conditioned media was sufficient enough to conclude that they are 
Chlamydia-specific across all treatment conditions.  (i) Initial; (P) Post; (DD) DEAE-dextran. 
 
4.8 Toll-like receptor expression on THP-1 monocyte and macrophage cell surfaces 
  
THP-1 Mn and Mϕ were stained (green) with antibodies against human TLR2 
(hTLR2) or hTLR4 to view receptor expression by immunofluorescence (40x). Cell 
surface expression of these PRRs is well represented (figs. 23a-23d and fig. 24) on 




































Figure 23. TLR expression on THP-1 Mn and Mϕ. THP-1 Mn or Mϕ were stained with antibodies 
against TLR2 or TLR4 and viewed under fluorescence microscopy.  TLR2 expression on Mn (a); TLR2 
expression on Mϕ (b); TLR4 expression on Mn (c); TLR4 expression on Mϕ (d).  Expression on Mn was 













Figure 24. TLR expression on THP-1 Mn.  TLRs on THP-1 Mn (pulsed by VCG, EB, or LPS) were 
stained (green) using antibodies against hTLR2 or hTLR4.  Nuclei were stain with DAPI (blue).  Images 
were taken at 40X magnification.   
 
THP-1 Mn and Mϕ (fig. 23) were stained for TLR expression then THP-1 Mn that 
had been pulsed by VCG, EBs, or LPS (fig. 24) were stained for TLR expression.  TLR 
expression was comparable, but higher in “nude” cells.  Nuclei were stained with DAPI 
(blue).  Images were taken at 40X magnification using Axiovision software 4.8.2 with a 






   





for DAPI.  Images demonstrate the expression of TLR2 and TLR4 (green) on the cell 
surface.  TLR expression was greatest on cells pulsed by VCG, and slightly less on cells 
pulsed by either EBs or LPS (fig. 24). 
4.9 Vibrio cholerae ghosts induce immune signaling through MyD88 recruitment 
and NFκB p65 activation in THP-1 monocytes and macrophages  
 
THP-1 Mϕ have cell surface receptors that recognize intrinsic properties 
contained on the bacterial ghost envelope that are not denatured during the production of 
the ghosts.  Cells were pulsed with VCG (10 ug/mL) for 4 – 6 h, then the cell lysate was 
analyzed by Western blot for protein expression of NFκB p65 or MyD88.  NFκB p65 
belongs to the Rel family of transcription factors. In most cells, NFκB p65 homo and 
heterodimers are retained in an inert, non-DNA-binding form in the cytosol by inhibitory 
molecules (e.g., IκB proteins). Activation of NFκB p65 occurs predominantly through 
phosphorylation and degradation of IκB proteins following cell surface receptor 
stimulation.  Purified NFκB p65 ABfinity™ Recombinant Rabbit Monoclonal Antibody 
was used to detect the NFκB p65 protein (fig. 25) which has a band detected at ~60 kDa 
developed by chemiluminescence. Lanes 1 - 6 all showed expression of the transcription 
factor.  Lane 1 represents lysate of cells pulsed by VCG alone.  Lane 2 represents lysate 
of cells pulsed by VCG and EBs.  Lane 3 represents lysate of cells pulsed by EBs alone. 
Lane 4 represents lysate from cells pulsed by Pam3CSK4 (a TLR2 ligand).  Lane 5 
represents lysate from cells pulsed by LPS (TLR4 ligand). Lane 6 represents lysate from 
our negative control where cells remained untreated in RPMI 1640 culture medium (fig. 









Figure 25. Characterization of NFκB p65 and MyD88 by Western blot analysis. THP-1 macrophages 
were pulsed under different conditions: VCG; VCG + EBs; elementary bodies (EBs); Pam3CSK4, a TLR2 
ligand; LPS, the TLR4 ligand or RPMI 1640 as a negative control.  Expression of NFκB p65 was detected 
at ~60 kDa when THP-1 MΦ were pulsed by VCG or LPS. MyD88 dimer was detected at 60 kDa under all 
treatment conditions and constitutively in the negative control, RPMI 1640. 
 
MyD88 is known to function as an adaptor protein in the interleukin (IL)-1 
signaling pathway for the association of IRAK (interleukin-1-receptor associated kinase) 
with the IL-1 receptor (123-125). MyD88 contains a characteristic N-terminal death 
domain that is essential for NFκB activation (126).  MyD88 also plays an important role 
in the inflammatory response induced by endotoxin (127).  Rabbit anti-MyD88 
(Invitrogen) was used to detect the MyD88 dimer (fig. 25) at ~60kDa developed by 
chemiluminescence. Lanes 1 - 6 all showed expression of the transcription factor.  Lane 1 
represents lysate of cells pulsed by VCG alone.  Lane 2 represents lysate of cells pulsed 
by VCG and EBs.  Lane 3 represents lysate of cells pulsed by EBs alone. Lane 4 
represents lysate from cells pulsed by Pam3CSK4 (a TLR2 ligand).  Lane 5 represents 
lysate from cells pulsed by LPS (TLR4 ligand). Lane 6 represents lysate from our 












Undeterred by the obvious limitations of their obligate intracellular niche, 
Chlamydiae are extraordinarily successful pathogens that infect and cause disease in 
animals at nearly every level of taxonomy.  In humans, chlamydial infections are the 
leading cause of preventable blindness and sexually transmitted infections and can also 
cause respiratory infections and other chronic disease sequelae.  Most disturbing, 
Chlamydia trachomatis poses a significant risk in women of child-bearing age, often 
leading to pelvic inflammatory disease, ectopic pregnancy, and infertility. 
This study sought to elucidate some of the molecular mechanisms involved in the 
induction of immune responses to chlamydia infection.  To do this we employed a 
veteran vaccine candidate vector, Vibrio cholerae ghosts, and investigated the immune 
response induced when using VCG as an adjuvant and the immune mediated signaling 
pathways activated following VCG stimulation.  Furthermore, we sought to determine 
MyD88-dependent mechanisms involved in VCG-mediated adaptive immunity and what 
functional role NF-κB plays in immune induction.  
Developing a long-term, cross-protective prophylactic against Chlamydia has 
been a challenge for many researchers for many years.  The primary reason is this 






pathogen attaches to its host, it is secreting proteins that fool its host into believing it is 
“friendly”.  Although, the host isn’t always fooled, as depending on the health of the host,  
the immune response could be efficient enough to recognize the threat and produce a 
variety of immunomodulatory molecules.  One of these molecules, known as cytokines, 
is IFNγ, which induces several antimicrobial mechanisms, including the breakdown of 
tryptophan, an amino acid required for the synthesis of protein by the pathogen.  
Although, this is usually just a temporary “fix” as the pathogen will morph into a 
persistent state until the “coast is clear” for it to re-enter its infectious cycle.  The 
effectiveness of Chlamydia trachomatis prevention is through antigen presentation.  The 
goal is to develop a prophylactic that prevents attachment of the pathogen. 
Traditional approaches to vaccine development have been ineffectual, mainly 
because we have yet to gain a thorough understanding of Chlamydia immunobiology. 
The current vaccine against Chlamydia does not provide long-term protection.  It has 
been suggested that a multi-subunit prophylactic (3, 110) in the form of a vaccine would 
provide a protective advantage over current treatments.  And although promising results 
have been observed in murine models, none of these are headed to clinical trial in 
humans. Currently infections caused by C. trachomatis are treated with antimicrobial 






The innate immune system contains germline-encoded pattern recognition 
receptors (PRRs); among them are TLR2 and TLR4.  They detect pathogens threat and 
trigger prompt responses against them (111).  These signaling molecules respond to 
bacterial lipoproteins and have been implicated in innate immunity and inflammation 
(112). TLR2 is expressed by the myeloid lineage, including macrophage and dendritic 
cells (113).  TLR4, along with its adapter proteins, is responsible for LPS recognition and 
signaling (114).  Lipoproteins are well-defined molecular patterns of Chlamydia 
trachomatis as well as a large variety of pathogenic microorganisms with the capability 
to stimulate antigen presenting cells (APCs).  They are strong cytokine inducers and have 
become a basis for vaccine development, making them key molecules in innate and 
adaptive immunity (115).  There are two possible routes for mediation of signals received 
by TLRs depending on which of the two adapter molecules, myeloid differentiation 
factor 88 (MyD88) and TIR-domain containing adapter-inducing interferon-β (TRIF), are 
involved.  The importance of MyD88 and TRIF lies in the finding that each leads to a 
distinct profile of immune mediators that in turn determine the phenotype of the cells that 
are primarily responsible for the development of adaptive immune responses (67-70).  An 
illustration of these immune responses is shown in figure 26 (128). Upon stimulation with 
various TLR ligands followed by recruitment of MyD88 or TRIF to the receptor 
complex, several phosphorylation events downstream allow NF-κB to be released into the 








Figure 26. TLR-mediated immune responses. TLR2 in concert with TLR1 or TLR6 discriminates 
between the molecular patterns of triacyl- and diacyl-lipopeptide, respectively. TLR3 recognizes dsRNA. 
TLR4 recognizes bacterial LPS. TLR7/8 mediates recognition of imidazoquinolines and ssRNA. TLR9 
recognizes CpG DNA of bacteria and viruses. TLR5 recognizes bacterial flagellin.  TLR1/2 and TLR2/6 
utilize MyD88 and TIRAP/MAL as essential adapters. TLR3 utilizes Trif. TLR4 utilizes four adapters, 
including MyD88, TIRAP/MAL, Trif and TRAM. TLR7/8, TLR9, TLR5 and TLR11 use only MyD88. 
The MyD88-dependent pathway controls inflammatory responses, while Trif mainly mediates type I IFN 
responses. In addition, TLR7/8 and TLR9 induce type I IFN in a MyD88-dependent manner in pDCs (128). 
 
Adaptive immunity to Chlamydia infection can be elicited by noncognate stimuli, 
although poorly understood.  The adaptive immune response to infection produces a large 
population of antigen-specific effector T cells with appropriate functional activities to 
combat invading microbes (118).  Innate immune response during an extended 
Chlamydia infection drives T cell clonal expansion whereby effector T cells can later be 
activated rapidly by a variety of noncognate stimuli.  Long-term, protective immunity is 





sequelae.  Moreover, a robust T helper 1 response along with complimentary antibody 
titer is required for swift, and efficient clearance and to down-regulate inflammation.  
It is worth mentioning the contribution hormones make in combating microbial 
infections.  Unique immunological features of the female genital tract (FGT) mucosa 
differentiate from the common mucosal immune system of organs such as the lungs or 
intestine.  The FGT mucosa lacks organized lymphoepithelial structures, but contains 
discrete lymphoid aggregates.  Sex hormones create a balance between tolerance to 
infection and immunity to infection.  In addition to the sex hormones, the menstrual cycle 
influences the immune response.  The mechanisms that promote protective immunity in 
the FGT (119) are regulated by changes in the female sex hormones.  However, it is less 
understood how female sex hormones affect the innate immune response of the FRT 
(female reproductive tract) epithelial cells, the initial cell type targeted by Chlamydia 
(120). 
The roles that TLRs, MyD88 and NF-κB play in protective immunity and the 
molecular mechanisms involved following immunization by a VCG-based vaccine and 
that activate these molecules was demonstrated by the identification of intrinsic ligands 
on the VCG envelope.  The bacterial ghost platform has been studied for decades.  The 
advantages of this system are far reaching for vaccine development and its use in cancer 
and infectious disease therapies.  The disadvantages however, are  that 1) the levels of 
immune effectors produced are insubstantial to confer either sterilizing or long-term 





mucosal sites of infection in order to determine the most appropriate route of 
immunization that will optimize protective immunity against Chlamydia (121). 
As an adjuvant, VCG offer some advantages for boosting the immune response.    
However, the mechanism(s) by which this system is used for immunization to stimulate 
immunity must induce long-term stimulation of both the humoral and cell-mediated 
immunity. 
The bacterial ghosts envelope maintain highly conserved structures which 
immune cells recognize – termed pathogen associated molecular patterns (PAMPs) – e.g., 
lipopolysaccharides and outer membrane protein A (OmpA).  Vibrio cholerae ghosts, the 
system used in this study, is a Gram-negative bacterium, and like Chlamydia trachomatis, 
both have similar outer membrane structure (Table 1).  We rationalized that the target 
epithelial cells have Toll-like receptors that can be stimulated by VCG bacterial vector.  
Furthermore, this epithelial cell stimulation leads to an induction of a VCG-specific 
immune response and signaling pathway, which in turn can enhance the immune 
response to Chlamydia infection.  Adjuvanticity is an innate property with 
immunopotency; just one of the important reasons for utilizing this vaccine system. 
Additionally, there is no size limitation of the foreign protein moieties – multiple 
antigenic determinants can be presented simultaneously; bacterial ghosts can be produced 
inexpensively in large quantities; recombinant ghosts are stable for long periods of time 
and do not require cold chain storage; inactivation procedures that denature relevant 





or as carriers of relevant antigens; and, the recombinant proteins are inserted into a highly 
immune stimulatory environment (122). 
 
Table 1. Comparison of structure and property similarity between V. cholerae and 








Chlamydia trachomatis is an obligate intracellular bacterium that causes 
Chlamydia infection annually in an estimated 4 million people in the United 
States and an estimated 92 million people worldwide.  It is the most common 
sexually transmitted infection caused by bacteria in the United States.  Treating 
the infection has been limited to antibiotic therapy and a vaccine - neither of 
which provides long-term, protective immunity against reinfection.  Most 
chemotherapeutic molecules, such as antibiotics, are designed to target bacteria.  
However, this therapy does not discriminate between the Chlamydia pathogen and 
the normal human flora (which is often crucial to keep the body healthy). 
Therefore, these studies on Vibrio cholerae ghosts as an adjuvant to treating 
Chlamydia infections may contribute to our current knowledge of the 
immunomodulatory response during infections and treatments which may 
improve therapeutics that prevent and manage its growth and spread.  The 
bacterial ghost platform is well studied and offers a promising therapeutic 
approach that is not only low-cost, but also free of any side effects.  Our overall 
hypothesis is that the effectiveness of CT prevention is via antigen presentation.  






in the induction of Chlamydia infection immune responses have investigated the 
mechanism of T cell control and the role of nitric oxide (123), and integrin-
mediated epithelial-T cell interaction with nitric oxide (124).   In the current study 
we sought to elucidate the molecular mechanisms involved in the induction of 
Chlamydia infection immune responses by a V. cholerae ghost-based vaccine 
vector, with our goal being to determine the involvement of MyD88-dependent 
TLR signaling and evaluate the functional role of NF-κB signaling in the immune 
response induced by our VCG-based vaccine vector.  Our results showed that the 
V. cholerae ghost vaccine vector induced a molecular pathway leading to the 
production of immunomodulatory factors capable of enhancing the immune 
response to Chlamydia infection.  Immune factors produced from pulsing THP-1 
monocytes or macrophages with VCG were comparable too or greater than those 
immune factors produced by Chlamydia EBs.  Additionally, the signaling 
pathways VCG activated – PI3K and MAPK – are also activated during 
Chlamydia infection. This was evidenced by gene expression of TLR2 and TLR4, 
and subsequent protein expression of MyD88 and NF-κB. MyD88-dependent 
mechanisms involved in VCG-mediated adaptive immunity were evidenced by 
the immunomodulatory response, specifically the activation of NF-κB followed 






is able to enhance the phagocytic capability of Mϕ, which may promote 
engulfment and elimination of CT.  The molecular mechanisms observed as a 
result of investigating the adjuvant properties of VCG could provide a rational 
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